Abstract Number: 115 • 2015 ACR/ARHP Annual Meeting
Validation of a Large Rheumatoid Arthritis Cohort and Preventive Health Screening
Background/Purpose: We extracted a large cohort of rheumatoid arthritis (RA) patients, on which we plan to apply big data analytics for earlier diagnosis of RA.…Abstract Number: 1440 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Carotid Plaques in RA Patients Are Associated with Increased HDL Function
Background/Purpose Reverse cholesterol transport (RCT) is a major anti atherogenic function of high density lipoprotein cholesterol (HDL) and has been shown to be related to…Abstract Number: 1361 • 2014 ACR/ARHP Annual Meeting
Rheumatologists’ Attitudes on Cardiovascular Risk and Lipid Screening in Patients with Rheumatoid Arthritis at an Academic Medical Center
Background/Purpose: Cardiovascular (CV) disease is a major cause of morbidity and mortality in the rheumatoid arthritis (RA) population. Thus, the recognition and management of cardiovascular…Abstract Number: 1274 • 2014 ACR/ARHP Annual Meeting
Patients with Osteoarthritis Do NOT Have Increased Risk of Cardiovascular Disease in Ullensaker Community in Norway
Background/Purpose Controversies exist regarding whether patients with osteoarthritis (OA) have an increased risk of cardiovascular (CV) disease. Our aim was to evaluate the CV risk…Abstract Number: 1123 • 2014 ACR/ARHP Annual Meeting
Impact of Genes Modulating Serum Low-Density Lipoprotein Cholesterol Levels on Progression of Joint Destruction in Japanese Patients with Rheumatoid Arthritis
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher prevalence of dyslipidemia than healthy individuals. Since RA is a chronic inflammatory disease, an inflammatory response…Abstract Number: 1063 • 2014 ACR/ARHP Annual Meeting
Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis in the Primary Care Setting
Background/Purpose: Rheumatoid arthritis has been associated with an increased risk of cardiovascular morbidity and mortality. It is unclear, however, whether this knowledge has translated into…Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting
Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…Abstract Number: 2465 • 2014 ACR/ARHP Annual Meeting
Cyclic Phosphatidic Acid (cPA) Suppresses MMP-3, a Disintegrin and Metalloproteinase with Thrombospondin Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in Inflammatory Rheumatoid Synovial Fibroblasts Induced with IL-1β and/or TNF-α
Background/Purpose Cyclic phosphatidic acid (cPA) is one of bioactive lipid, has been implicated as an mediator of various biological effects including i) antiproliferative effect on…Abstract Number: 2305 • 2014 ACR/ARHP Annual Meeting
Improving Screening for Hyperlipidemia in Patients with Rheumatoid Arthritis at an Academic Rheumatology Practice
Background/Purpose Cardiovascular disease is the leading cause of mortality in the rheumatoid arthritis (RA) population. However, cardiovascular risk factors such as hyperlipidemia are undertreated in…Abstract Number: 1441 • 2014 ACR/ARHP Annual Meeting
Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function
Background/Purpose: The cardiovascular comorbidity seen in early treatment naive rheumatoid arthritis (RA) can be considered as an aspect of ´´accelerated aging``. Methods: We investigated cell…Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting
Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients
Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…Abstract Number: 2309 • 2013 ACR/ARHP Annual Meeting
Quantifying The Gap Between General Population Guidelines and Expert Opinion For Cardiovascular Risk Management In Rheumatic Disease Patients
Background/Purpose: Cardiovascular (CV) risk is higher among rheumatic disease patients than the general population. However, CV risk management guidelines calibrated for the rheumatic disease population…Abstract Number: 1280 • 2013 ACR/ARHP Annual Meeting
The Role of Sphingosine-1-Phosphate Receptor 3 Signaling in Murine Collagen-Induced Arthiritis
Background/Purpose: Sphingolipids represent a major class of lipids that are ubiquitously expressed in eukaryotic cell membranes. Through the interaction with a family of five G-protein-coupled…Abstract Number: 1166 • 2013 ACR/ARHP Annual Meeting
Anti-Inflammatory Property Of HDL In NOD1 Ligand Induced Kawasaki Arteritis In Mice
Background/Purpose: Atherosclerosis is a chronic metabolic disease of inflammatory processes. Immune cells including monocytes are recruited to the subintimal lesion of the vascular wall and…